Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 29 · below the Ichimoku cloud · RSI 15 (oversold) · MACD above its signal · 9% above its 52-week low
| 17,750.00 | 52-week high | +34872198.62% |
| 1.37 | Previous month high | +2593.52% |
| 0.1190 | Previous week high | +133.79% |
| 0.0650 | Previous week low | +27.70% |
| 0.0650 | Previous month low | +27.70% |
| 0.0563 | R3 (classic) | +10.67% |
| 0.0537 | R2 (classic) | +5.44% |
| 0.0523 | R1 (classic) | +2.82% |
| 0.0510 | Previous day high | +0.20% |
| 0.0509 | Price now | |
| 0.0497 | Pivot | −2.42% |
| 0.0483 | S1 (classic) | −5.04% |
| 0.0470 | Previous day low | −7.66% |
| 0.0470 | 52-week low | −7.66% |
| 0.0457 | S2 (classic) | −10.28% |
| 0.0443 | S3 (classic) | −12.90% |
None of the 29 investors followed here reported a position in CDT in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CDT trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for CDT.
TimeframesDown on the hourly, daily and monthly, mixed on the weekly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.8 | -36.4 | -70.6 | -54.4 | -55.3 | -46.2 | -47.7 | -42.7 | -96.8 | -95.0 | -25.1 | −100.0% | |
| 2025 | -64.1 | -51.6 | -34.9 | -28.6 | -61.2 | -15.1 | -35.5 | -25.3 | -48.9 | -47.8 | -28.5 | -36.9 | −99.8% |
| 2024 | -42.4 | -1.9 | 42.8 | -18.0 | 1.0 | -65.1 | -78.1 | -47.0 | -3.3 | -23.5 | 17.6 | -35.5 | −98.5% |
| 2023 | 0.6 | 0.4 | 1.6 | -0.4 | 1.2 | 0.8 | 0.8 | -0.9 | -44.1 | -69.7 | 158.6 | -2.8 | −55.6% |
| 2022 | 0.5 | -0.3 | 0.6 | -0.1 | 0.4 | 0.4 | 0.5 | 0.0 | 1.0 | +3.0% |
No analyst coverage for this instrument.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.